Skip to main content

and
  1. No Access

    Article

    Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial

    The domestic prevalence of chronic hepatitis B (CHB) in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot(s)ide analogues (NUCs) anti-hepatitis B virus (HBV) therapies are widely appl...

    Yong-an Ye, **ao-ke Li, Da-qiao Zhou in Chinese Journal of Integrative Medicine (2018)

  2. No Access

    Article

    Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial

    To evaluate the effects of a 48-week course of adefovir dipivoxil (ADV) plus Chinese medicine (CM) therapy, namely Tiaogan Jianpi Hexue (调肝健脾和血) and Tiaogan Jiedu Huashi (调肝解毒化湿) fomulae, in hepatitis B e anti...

    **ao-ke Li, Ming-xiang Zhang, Feng-zhen Shao in Chinese Journal of Integrative Medicine (2020)

  3. Article

    Open Access

    Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multi-center, double-blind, randomized controlled trial in China

    Nucleos(t)ide analogues (NAs) are the first-line option against chronic hepatitis B (CHB). NAs produce potent suppression of viral replication with a small chance of HBsAg seroclearance and a high risk of viro...

    **aoke Li, Ludan Zhang, Mei Qiu, Yi Huang, Huanming **ao, Bingjiu Lu in Trials (2020)

  4. No Access

    Article

    Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

    Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether ...

    **aoke Li, Daqiao Zhou, **aoling Chi, Qin Li, Li Wang in Hepatology International (2020)

  5. Article

    Open Access

    The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification

    The Chinese herbal formula TiaoGanYiPi (TGYP) showed effective against chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) infection. Hence, we aimed to clarify the mechanisms and potential targets bet...

    Xu Cao, **aobin Zao, Baiquan Xue, Hening Chen, Jiaxin Zhang, Shuo Li in Scientific Reports (2021)

  6. Article

    Open Access

    The host immune response of a discharged COVID-19 patient with twice reemergence of SARS-CoV-2: a case report

    The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. There have been reports that long-term SARS-CoV-2 RNA shedding and r...

    **aobin Zao, Yang Zhou, Yijun Liang, Xu Cao, Hening Chen in BMC Infectious Diseases (2021)

  7. Article

    Open Access

    Histologic changes in immune-tolerant patients with chronic hepatitis B: a systematic review and meta-analysis

    The serological diagnostic criteria for the immune-tolerant (IT) phase have not been strictly defined and it is hard to determine an accurate rate for significant histologic changes among IT patients. The aim ...

    Zhiguo Li, Dongliang Yang, Yue Ge, Shu Song, Qin Lv, Yong’an Ye in Scientific Reports (2023)

  8. Article

    Open Access

    Association between leptin and NAFLD: a two-sample Mendelian randomization study

    The etiology of nonalcoholic fatty liver disease (NAFLD) involves a complex interaction of genetic and environmental factors. Previous observational studies have revealed that higher leptin levels are related ...

    Ziwei Guo, Hongbo Du, Yi Guo, Qian **, Ruijia Liu in European Journal of Medical Research (2023)